DE60039036D1 - Hiv-peptide, antigene und impfstoffzusammensetzungen - Google Patents

Hiv-peptide, antigene und impfstoffzusammensetzungen

Info

Publication number
DE60039036D1
DE60039036D1 DE60039036T DE60039036T DE60039036D1 DE 60039036 D1 DE60039036 D1 DE 60039036D1 DE 60039036 T DE60039036 T DE 60039036T DE 60039036 T DE60039036 T DE 60039036T DE 60039036 D1 DE60039036 D1 DE 60039036D1
Authority
DE
Germany
Prior art keywords
hiv
peptides
antigens
vaccine compositions
antigenes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60039036T
Other languages
English (en)
Inventor
Birger Soerensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bionor Immuno AS
Original Assignee
Bionor Immuno AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionor Immuno AS filed Critical Bionor Immuno AS
Application granted granted Critical
Publication of DE60039036D1 publication Critical patent/DE60039036D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
DE60039036T 1999-03-04 2000-03-02 Hiv-peptide, antigene und impfstoffzusammensetzungen Expired - Lifetime DE60039036D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO19991078A NO311807B1 (no) 1999-03-04 1999-03-04 HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV
PCT/NO2000/000075 WO2000052040A1 (en) 1999-03-04 2000-03-02 Hiv peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv

Publications (1)

Publication Number Publication Date
DE60039036D1 true DE60039036D1 (de) 2008-07-10

Family

ID=19903050

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60039036T Expired - Lifetime DE60039036D1 (de) 1999-03-04 2000-03-02 Hiv-peptide, antigene und impfstoffzusammensetzungen

Country Status (23)

Country Link
US (4) US6706859B1 (de)
EP (1) EP1159298B1 (de)
JP (5) JP2002541069A (de)
CN (4) CN101328209A (de)
AT (1) ATE397014T1 (de)
AU (1) AU771827B2 (de)
BR (1) BR0008741A (de)
CA (1) CA2363947C (de)
CY (1) CY1108299T1 (de)
CZ (1) CZ300505B6 (de)
DE (1) DE60039036D1 (de)
DK (1) DK1159298T3 (de)
EA (1) EA004802B9 (de)
ES (1) ES2307496T4 (de)
HK (1) HK1044778B (de)
HU (1) HU229282B1 (de)
ID (1) ID30497A (de)
NO (1) NO311807B1 (de)
NZ (4) NZ514619A (de)
PT (1) PT1159298E (de)
SK (1) SK287382B6 (de)
WO (1) WO2000052040A1 (de)
ZA (1) ZA200107072B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2398816A1 (en) 2000-02-04 2001-08-09 Duke University Human immunodeficiency virus vaccine
NO314587B1 (no) * 2000-09-04 2003-04-14 Bionor Immuno As HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV
NO314588B1 (no) 2000-09-04 2003-04-14 Bionor Immuno As HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV
DK2392587T3 (en) 2006-03-10 2016-05-23 Peptcell Ltd Peptide sequences and compositions
JP5775451B2 (ja) 2008-06-19 2015-09-09 バリエーション バイオテクノロジーズ インコーポレイティド インフルエンザを処置するための組成物および方法
WO2011005772A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
BR112012000826B1 (pt) 2009-07-06 2022-07-26 Variation Biotechnologies Inc Método para a preparação de vesículas
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
JP6119030B2 (ja) 2010-07-06 2017-04-26 ヴァリエーション バイオテクノロジーズ インコーポレイテッド インフルエンザを治療するための組成物及び方法
EP2646459B1 (de) * 2010-12-02 2020-01-08 Bionor Immuno AS Peptidgerüstentwurf
EP2663327A4 (de) 2011-01-13 2015-12-02 Variation Biotechnologies Inc Zusammensetzungen und verfahren zur behandlung von virusinfektionen
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
WO2013104995A2 (en) 2012-01-12 2013-07-18 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
EP2806894A4 (de) 2012-01-27 2015-11-04 Variation Biotechnologies Inc Verfahren und zusammensetzungen für therapeutika
JP2015520179A (ja) * 2012-06-06 2015-07-16 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ ワクチン
JP6310909B2 (ja) * 2012-06-06 2018-04-11 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ 免疫原及び投薬反応物として使用するためのウイルスタンパク質に由来するペプチド
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
WO2015007337A1 (en) 2013-07-19 2015-01-22 Bionor Immuno As Method for the vaccination against hiv
EP3033106A1 (de) * 2013-08-14 2016-06-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Immunadjuvanzienzusammensetzungen und verwendungen davon
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (de) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
WO2015086738A2 (en) * 2013-12-11 2015-06-18 Bionor Immuno As Hiv vaccine
WO2015110666A1 (en) 2014-01-27 2015-07-30 Bionor Immuno As Method for the vaccination against hiv
US10449245B2 (en) 2014-01-27 2019-10-22 Bionor Immuno As Method for reducing HIV-1 reservoir size using multivalent immunogen and reservoir purging agent
WO2015110659A1 (en) * 2014-01-27 2015-07-30 Bionor Immuno As Methods of immunization with a vaccine inducing a humoral immune response and with a vaccine inducing a cellular immune response
WO2015154031A1 (en) 2014-04-03 2015-10-08 Amgen Inc. Method for preparing amg 416
EP3166633A1 (de) 2014-07-11 2017-05-17 Bionor Immuno AS Verfahren zur reduktion und/oder verzögerung der pathologischen wirkungen des menschlichen immunschwächevirus i (hiv) oder zur verringerung des risikos der entwicklung von erworbenem immundefizienzsyndrom (aids)
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
US20180140694A1 (en) 2015-05-04 2018-05-24 Bionor Immuno As Dosage regimen for hiv vaccine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0230222A1 (de) 1986-01-06 1987-07-29 F. Hoffmann-La Roche Ag Expression des HTLV-III Gag-Gens
US4925784A (en) 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
GB8629116D0 (en) 1986-12-05 1987-01-14 Hoffmann La Roche Env/gag polypeptides
NZ226026A (en) 1987-09-04 1991-03-26 Wellcome Found Immunoassay for an antibody using recombinant antigens expressed in two different genera
US4888290A (en) * 1987-11-06 1989-12-19 Coulter Corporation Monoclonal antibody specific to HIV antigens
EP0356007A3 (de) 1988-07-22 1991-07-03 Medical Research Council Antigenische Determinanten
KR940000755B1 (ko) * 1990-02-16 1994-01-29 유나이티드 바이오메디칼 인코오포레이티드 Hcv에 대한 항체 검출, hcv 감염의 진단 및 백신으로서의 그 예방에 특히 적합한 합성 펩티드
SE468168B (sv) 1990-02-20 1992-11-16 Replico Medical Ab Hiv-1, p24 peptider, diagnostiska antigener och foerfarande foer saerskiljande diagnostik av preliminaert hiv-1 positiva serumprov
US5288514A (en) * 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
FR2703252B1 (fr) * 1993-03-31 1996-09-06 Fernand Narbey Torossian Complexe immunomodulateur anti SIDA.
AU7101294A (en) * 1993-06-07 1995-01-03 Endocon, Inc. Implant stimulated cellular immunity
CA2173138A1 (en) * 1993-10-19 1995-04-27 Masafumi Takiguchi Peptide capable of inducing immune response against hiv and aids preventive or remedy containing the peptide
FR2731013B1 (fr) * 1995-02-27 1997-05-16 Inst Nat Sante Rech Med Vih-1 de groupe o, fragments desdits virus, ainsi que leurs applications
AU6727798A (en) * 1997-03-10 1998-09-29 Roche Diagnostics Gmbh Method for simultaneous detection of hiv antigens and hiv antibodies

Also Published As

Publication number Publication date
PT1159298E (pt) 2008-09-04
EP1159298A1 (de) 2001-12-05
BR0008741A (pt) 2002-01-08
SK12402001A3 (sk) 2002-02-05
NZ525751A (en) 2004-10-29
US7709003B2 (en) 2010-05-04
HK1044778A1 (en) 2002-11-01
ES2307496T4 (es) 2015-03-06
JP5695010B2 (ja) 2015-04-01
CA2363947C (en) 2008-05-20
CZ20013195A3 (cs) 2002-02-13
EP1159298B1 (de) 2008-05-28
HUP0200265A2 (en) 2002-06-29
CZ300505B6 (cs) 2009-06-03
US20080107670A1 (en) 2008-05-08
CN101328210A (zh) 2008-12-24
AU771827B2 (en) 2004-04-01
CY1108299T1 (el) 2014-02-12
WO2000052040A1 (en) 2000-09-08
JP2002541069A (ja) 2002-12-03
CN100387617C (zh) 2008-05-14
CN1346367A (zh) 2002-04-24
CN101328208A (zh) 2008-12-24
JP5814331B2 (ja) 2015-11-17
NZ514619A (en) 2003-10-31
US7311915B2 (en) 2007-12-25
JP5695012B2 (ja) 2015-04-01
US20040259797A1 (en) 2004-12-23
JP2013032384A (ja) 2013-02-14
HU229282B1 (en) 2013-10-28
NZ525753A (en) 2004-10-29
CA2363947A1 (en) 2000-09-08
JP2014043468A (ja) 2014-03-13
EA200100943A1 (ru) 2002-02-28
CN101328209A (zh) 2008-12-24
EA004802B9 (ru) 2015-03-31
NO991078L (no) 2000-09-05
JP2011074081A (ja) 2011-04-14
DK1159298T3 (da) 2008-08-25
NO991078D0 (no) 1999-03-04
JP2013032386A (ja) 2013-02-14
US7709004B2 (en) 2010-05-04
NO311807B1 (no) 2002-01-28
JP5313998B2 (ja) 2013-10-09
EA004802B1 (ru) 2004-08-26
ZA200107072B (en) 2002-11-27
SK287382B6 (sk) 2010-08-09
ID30497A (id) 2001-12-13
HK1044778B (zh) 2009-04-24
NZ525752A (en) 2004-10-29
AU3335800A (en) 2000-09-21
ES2307496T3 (es) 2008-12-01
US6706859B1 (en) 2004-03-16
ATE397014T1 (de) 2008-06-15
US20080107669A1 (en) 2008-05-08

Similar Documents

Publication Publication Date Title
DE60039036D1 (de) Hiv-peptide, antigene und impfstoffzusammensetzungen
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
GILLJAM Envelope glycoproteins of HIV-1, HIV-2, and SIV purified with Galanthus nivalis agglutinin induce strong immune responses
MY103182A (en) Vaccines against acquired immune deficiency syndrome.
BR0210598A (pt) Complexo solúvel que compreende uma glicoproteìna retroviral de superfìcie
DE68927348D1 (de) Künstlicher impfstoff gegen aids-virus
WO2002020555A3 (en) Hiv peptides from tat, rev and wef conserved regions and their application as e.g.vaccine components
DE3855134D1 (de) Monoklonale menschliche antikörper gegen hiv-i
DE60044259D1 (de) HUMANE ANTI-CHEMOKINREZEPTOREN IgM ANTIKÖRPER
Lizeng et al. Serum immunoglobulin A (IgA)-mediated immunity in human immunodeficiency virus type 2 (HIV-2) infection
Pyle et al. Purification and characterization of the external envelope glycoprotein from two human immunodeficiency virus type 1 variants, HTLV-IIIB and HTLV-IIIRF
FR2694938B1 (fr) Nouveaux peptides, anticorps diriges contre ces peptides, anticorps anti-idiotypiques, application a titre de medicaments, compositions pharmaceutiques et kits de diagnostic les renfermant.
AU4832097A (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
Chen et al. A common immunological epitope existing between HIV-1 gp41 and human interferon-α and-β
Benjamini et al. Isolation and characterization of the neutralizable epitope of simian retrovirus-1 (SRV-1) and of the cell receptor for the virus
ATE122236T1 (de) Vorläufer des hüllenglykoproteins des hiv-2 retrovirus und verwandte antigene.
FR2874017B1 (fr) Peptides vih-1 modifies et leur utilisation en detection d'anticorps anti-vih
TH62264A (th) Hiv เพพไทด์, แอนติเจน องค์ประกอบวัคซีน, ชุดสำเร็จรูปอิมมูโนแอสเสย์ และวิธีสำหรับตรวจหาแอนติบอดีที่ชักนำโดย hiv
RU2000106709A (ru) Пептиды-имитаторы консервативного эпитопа белка gp41 вируса иммунодефицита человека типа 1, узнаваемого вируснейтрализующими моноклональными антителами 2f5
BR9711809A (pt) Polipeptìdeo antigênico ou imunogênico, processos para tratar ou prevenir uma doença ou distúrbio em um indivìduo provocado por infecção com htlv-i, e com htlv-ii, para elicitar em um indivìduo a produção de anticorpos que especificamente ligam-se às proteìnas envelopes htlv-ii e htlv-i, e, para gerar uma resposta imune em um indivìduo
TH65071A (th) เพพไทด์ควบคุม และอนุเคราะห์ hiv แอนติเจน องค์ประกอบวัคซีนชุดสำเร็จรูปอิมมูโนแอสเสย์และวิธีการของการตรวจหาแอนติบอดีที่ถูกชักนำโดย hiv

Legal Events

Date Code Title Description
8364 No opposition during term of opposition